FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * Benedicto David C. 2. Date of Event Requiring Statement (MM/DD/YYYY)
5/23/2021 

3. Issuer Name and Ticker or Trading Symbol Adamis Pharmaceuticals Corp [ADMP]
(Last)       (First)       (Middle)
C/O ADAMIS PHARMACEUTICALS CORPORATION, 11682 EL CAMINO REAL, STE 300
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                          _____ 10% Owner
___X___ Officer (give title below)        _____ Other (specify below)
Principal Accounting Officer /
(Street)
SAN DIEGO, CA 92130      
(City)             (State)             (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)
 

6. Individual or Joint/Group Filing(Check Applicable Line)_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock  6387  D   
Common Stock  50645 (1) D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (right to buy)   (2) 12/1/2024  Common Stock  30000  $4.10  D   
Employee Stock Option (right to buy)   (3) 1/25/2026  Common Stock  18811  $4.10  D   
Employee Stock Option (right to buy)   (4) 2/7/2027  Common Stock  51000  $3.15  D   
Employee Stock Option (right to buy)   (5) 2/21/2028  Common Stock  104333  $2.83  D   

Explanation of Responses:
(1)  Represents restricted stock units (RSUs) granted to the Reporting Person on January 30, 2019. Each RSU represents a contingent right to receive one share of the issuer's common stock. The RSUs vest ratably over a period of approximately three years with respect to approximately 1/12 of the total number of RSUs on each on May 17, August 17, November 17 and March 17 of each year, provided that the Reporting Person has continued to provide services to the Company during such period. The RSUs vest earlier in connection with a Change in Control of the Company (as defined in the Plan and the applicable award agreement) or upon the death or disability of the Reporting Person, and the shares covered by the RSU are issuable following vesting as provided in the Plan and award agreement. The RSUs are granted pursuant to the 2009 Equity Incentive Plan and are subject to other provisions in the applicable award agreement.
(2)  The option vests and becomes exercisable as to 1/36 of the option shares on each monthly anniversary of the December 1, 2014 grant date, subject to the Reporting Person's continued service to the Issuer through such vesting date.
(3)  The option vests and becomes exercisable as to 1/36 of the option shares on each monthly anniversary of the January 25, 2016 grant date, subject to the Reporting Person's continued service to the Issuer through such vesting date.
(4)  The option vests and becomes exercisable as to 1/36 of the option shares on each monthly anniversary of the February 07, 2017 grant date, subject to the Reporting Person's continued service to the Issuer through such vesting date.
(5)  The option vests and becomes exercisable as to 1/36 of the option shares on each monthly anniversary of the February 21, 2018 grant date, subject to the Reporting Person's continued service to the Issuer through such vesting date.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Benedicto David C.
C/O ADAMIS PHARMACEUTICALS CORPORATION
11682 EL CAMINO REAL, STE 300
SAN DIEGO, CA 92130


Principal Accounting Officer

Signatures
/s/David C. Benedicto 6/2/2021
**Signature of Reporting Person Date
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From Jun 2021 to Jul 2021 Click Here for more Adamis Pharmaceuticals Charts.
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From Jul 2020 to Jul 2021 Click Here for more Adamis Pharmaceuticals Charts.